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Abstract
Background and Aim: The aim of this study was to examine the mechanisms of IFN induction and viral escape. In order to
accomplish the goal we compared our new hepatoma cell line LH86, which has intact TLR3 and RIG-I expression and
responds to HCV by inducing IFN, with Huh7.5 cells which lack those features.
Methods: The initial interaction of LH86 cells, Huh7.5 cells or their transfected counter parts (LH86 siRIG-I, siTLR3 or siTLR7
and Huh7.5 RIG-I, TLR3 or TLR7) after infection with HCV (strain JFH-1) was studied by measuring the expression levels of
IFNb, TRAIL, DR4, DR5 and their correlation to viral replication.
Results: HCV replicating RNA induces IFN in LH86 cells. The IFN induction system is functional in LH86, and the expression of
the RIG-I and TLR3 in LH86 is comparable to the primary hepatocytes. Both proteins appear to play important roles in
suppression of viral replication. We found that innate immunity against HCV is associated with the induction of apoptosis by
RIG-I through the TRAIL pathway and the establishment of an antiviral state by TLR3. HCV envelope proteins interfere with
the expression of TLR3 and RIG-I.
Conclusion: These findings correlate with the lower expression level of PRRs in HCV chronic patients and highlight the
importance of the PRRs in the initial interaction of the virus and its host cells. This work represents a novel mechanism of
viral pathogenesis for HCV and demonstrates the role of PRRs in viral infection.
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Introduction
Hepatitis C virus (HCV), a member of the family flaviviridae,
infects approximately 170 million people worldwide leading to
chronic liver disease in up to 80% of them [1,2]. Failure to induce
type I IFN, has been correlated with the lack of an appropriate
innate response [3,4]. In particular, chronically infected hepato-
cytes have a reduced expression of the pathogen recognition
receptors (PRRs) and levels of interferon a (IFNa) which correlate
with poor responses to standard treatment of care (Ribavirin and
pegylated IFN) [5,6]. How this down regulation occurs has not yet
been fully elucidated.
An important mechanism of initial immune response is through
the recognition of the virus’ genetic material by PRRs, such as
Toll-like receptors (TLR3 and TLR7 for RNA) and the cytosolic
receptor DexH(D) RNA helicase retinoic acid inducible gene-I
(RIG-I), followed by the induction of cytokines including type I
IFN [7,8,9,10]. This cytokine cascade starts with the binding of
foreign RNA to specific sites inside the receptor followed by the
coupling to adaptor molecules specific for each receptor (TRIF
and Cardif respectively) that converge at transcription factors
(IRF-3, NF-kB and ATF2/c-jun) in charge of genes related to the
amplification of the signal and initiation of adaptive responses
[9,11,12]. Both TLR3 and RIG-I share most of these pathways’
molecules and can in theory have complementary effects on most
cells. While these pathways are normally associated with the
induction of cytokines it was recently discovered that RIP-1, a
molecule normally associated with apoptosis by functioning
downstream of TNFR by TRADD interaction, is also associated
with TRIF or Cardif. This binding helps modulate the type of
response to either pro-inflammatory or pro-apoptotic effects in an
IRF-3-dependent manner [13,14,15]. Therefore, as long as both
pathways are active (before pathogenic disruption) type I IFNs,
pro-inflammatory cytokines and apoptosis can work together to
induce clearance.
In this report, we demonstrate that HCV can induce IFNb in
the acute phase of infection, and that TLRs and RIG-I are
involved in this process. Furthermore, we demonstrate that HCV
viral envelope proteins can have an effect on this system by down
regulation of these PRRs in vitro. This work demonstrates an
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21186indirect link between the actions of PRRs in viral infection which
represents a novel mechanism of viral pathogenesis for HCV.
Materials and Methods
Cells culture, reagents and plasmids
LH86 cells have been developed by our group from a resected,
well-differentiated, hepatocellular carcinoma and Huh-7.5 cells
were kindly provided by Dr. Charles M. Rice (Rockefeller
University, New York, NY)[16,17]. All cell lines were propagated
in DMEM supplemented with 10% FBS, 200 mM L-glutamine,
non-essential amino acids, penicillin, and streptomycin (complete
DMEM or cDMEM). The expression vector pTOPO was from
Invitrogen (Carlsbad, CA) and the negative control siRNA was
produced by T7 polymerase in vitro with the Ambion Silencer
siRNA construction Kit or purchased (both control and kit from
Ambion, Austin, TX). The plasmids for TLR3 and TLR7
(pUNO-hTLR3-HA and pUNO-hTLR7-HA) were purchased
from Invivogen (San Diego, CA) and the siRNAs targeting those
genes were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Core, Envelope E1/E2 and NS3/4A were amplified
from pJFH-1 plasmid and cloned using TOPO TA Cloning kit
from Invitrogen (Table 1 shows PCR primers used for amplifica-
tion).
Cells were transfected using Lipofectamine following the
manufacturer’s recommendations (Invitrogen). Briefly, in a 6-well
tissue culture plate (Fisherbrand), 1610
5 Huh7.5 or LH86 cells
were seeded in 2 mL of cDMEM and incubated at 37uC
overnight. The next day 2 mg of DNA diluted in a total of
20 mL serum free media and 20 mL of lipofectamine diluted to a
100 mL were incubated for 45 minutes at room temperature before
mixing. The mixture was incubated for another 15 minutes under
the same conditions. After this incubation the cells were mixed
with serum free media to a total 1 ml volume and layered on top
of prewashed adherent cells. The transfected cells were incubated
for another 24 hours before changing into complete DMEM.
Stable cell clones were selected using antibiotics for a minimum of
4 weeks. All experiments were observed daily by light microscopy
and cells collected for total RNA isolation with Trizol reagent
(Invitrogen, Carlsbad, CA). Poly (I:C) was obtained from
InvivoGen (San Diego, CA).
HCV constructs and viral particle generation
pJFH-1 plasmid and pJFH-1/GND plasmid (negative control)
were gifts from Dr. Takaji Wakita (Department of Virology II,
National Institute of Infectious Diseases, Tokyo, Japan) [18]. The
linearized DNA was purified and used as a template for in vitro
transcription using MEGAscript kit (Ambion, Austin, TX). In vitro
transcribed genomic JFH-1 or JFH-1/GND RNA was delivered
into Huh-7.5 cells by electroporation. The transfected cells were
transferred to complete DMEM medium and cultured for the
indicated period. Cells were passaged every 3–5 days and
corresponding supernatants were collected and filtered with a
0.45 mm filter device before freezing at 280uC. Viral titers were
expressed as focus-forming units per milliliter (ffu/mL) and
determined by the average number of NS5A-positive foci detected
at the highest dilution of a serial dilution culture using Huh-7.5 cell
line as host cells.
Reverse Transcription and Polymerase Chain Reaction
(RT-PCR)
RT-PCR of total RNA to obtain cDNA was performed using
the Superscript II (50 U reverse transcriptase per reaction) first-
strand synthesis for RT-PCR kit (Invitrogen) primed with oligo
(dT)12–18 (Invitrogen) according to the manufacturer’s instructions.
After reverse transcription, cDNA was used for quantitative real-
time RT-PCR using fluorophore-labeled LUX primers from
Invitrogen, or SYBR (Table 2) some of which we have published
before [19,20,21]. Reactions were conducted in a 96-well
spectrofluorometric thermal cycler (StepOne Plus Sequence
detector system, Applied Biosystems). Fluorescence was monitored
during every PCR cycle at the annealing step. Results were
analyzed with StepOne Plus software version 2.1 from Applied
Biosystems. The PCR conditions were as follows: 50uC, 2 min;
95uC, 2 min (Super UDG master mix, Invitrogen) or 10 min
(SYBR Green Master Mix, Applied Biosystems) and 40 cycles of
95uC, 15 s; 60uC–62uC (depending on the primer set), 30 s and
Table 1. Primer sets used for cloning.
59-TTGGATCCATGAGCACAAATCCTAAACC-39
Core 59-CGTCTAGATCAAGCAGAGACCGGAACGGTGAT-39
59-GCTCTAGAGCCCAGGTGAAGAATACCAG-39
E1/E2 59-CGGGATCCTCATGCTTCGGCCTGGCCCAACAAG-39
59-TTGGATCCATGGCTCCCATCACTGCTTATGCC -39
NS3/4A 59-CGTCTAGATCAGCATTCCTCCATCTCATCAAAAGCC-39
doi:10.1371/journal.pone.0021186.t001
Table 2. Primers sets used for Real time RT-PCR(D-Lux
primers show fluorochrome in the sequence).
59-CCTTCTTTAATGGTGGCTCCAT-39
HCV 39 UTR 59-GGCTCACGGACCTTTCACA-39
Probe: 59-TTAGCCCTAGTCACGGCT-39
59-CAGCCGATTCATCGAGCACTCGC[FAM]G-39
IFNb 59-TTCCAGGACTGTCTTCAGATGG-39
I-8U 59CACGGTCATAGCATTCGCCTACTCCG[FAM]G-39
59GTCACGTCGCCAACCATCTT-39
59-GACTGCTCGGAGGAGGACTCGCAG[FAM[C-39
G1P3 59CAGGATCGCAGACCAGCTCA-39
59-ATGGTACCTCATGGCTATGATGGAGGTC-39
TRAIL 59-AAGCGGCCGCTCATAGTGTATCATCCTGAAAACTGA-39
59-GGGTCCACAAGACCTTCAAGT-39
DR4 59-TGGTGTAACCCACACCCTCT-39
59-AGAGGGATTGTGTCCACCTG-39
DR5 59AATCACCGACCTTGACCATC-39
59-CATCTGCCTCCCCATATTCCT-39
RANTES (CCL5) 59-GCGGGCAATGTAGGCAAA-39
59-ATTATTCCTGCAAGCCAATTTTG-39
IP-10 (CXCL10) 59-TCACCCTTCTTTTTCATTGTAGCA-39
59-ACAACTTAGCACGGCTCTGGA-39
TLR3 59-ACCTCAACTGGGATCTCGTCA-39
59-GACTGGACGTGGCAAAACAA-39
RIG-I 59-TTGAATGCATCCAATATACACTTCTG-39
59-CGACCGGAGTCAACGGATTTGGT[JOE]G-39
GADPH 59-GGCAACAATATCCAGTTTAGCA-39
doi:10.1371/journal.pone.0021186.t002
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PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21186Figure 1. IFN response is dependent on viral replication. A) IFNb mRNA expression was measured daily from the total RNA of LH86 cells
treated with an MOI of 0.1 of HCV/JFH-1. The expression was calculated by the DDCt method where uninfected cells were the experimental control
and the housekeeping gene GAPDH was the internal control. Error bars represent the SEM of three separate experiments. The ‘‘No virus’’ control
indicates cells that were cultured with uninfected Huh7.5 supernatant, ‘‘HCV’’ is the supernatant from infected Huh7.5 cells as described in the
methods section (MOI=0.1), ‘‘heated HCV’’ is the same supernatant as ‘‘HCV’’ but heated for 15 minutes at 72uC and ‘‘UV-treated HCV’’ was exposed
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-DDCt method
following previously described calculations [22].
HCV copies were determined using a standard curve of JFH-1
full-length RNA transcribed in vitro. PCRs were run in duplicates
and overall data represents triplicate experiments and are
represented as means 6SEM. The Taqman FAM-labeled
primer-probe set used in our experiments was originally designed
for HCV genotype 1. Compared to genotype 2a there is a
mismatch in the forward primer in the ninth nucleotide (59 to 39).
However, this primer set was demonstrated in our laboratory to be
highly efficient, even more so than our previously published
59UTR primer when used with in vitro transcribed JFH-1.
Furthermore, most of the experiments carried here were
performed initially with both primers and similar results were
obtained.
Immunofluorescence
Cells were grown on glass coverslips later to be washed and
fixed on ice with 5% acetic acid in 100% ethanol (Fisherbrand).
Cells were washed with 1X PBS and incubated with either goat
anti-human TLR3 (Santa Cruz Biotechnology), goat anti-human
TLR7 (Santa Cruz Biotechnology), rabbit anti-human RIG-I
(ProSci Inc, Poway, CA) or mouse anti-HCV NS5A monoclonal
antibody (established at our institution) for 1 hour. The respective
secondary antibody (donkey anti-goat IgG FITC conjugated for
TLR3 and TLR7, goat anti-rabbit IgG FITC conjugated, goat
Figure 2. Both TLRs and RIG-I prevent viral replication and are needed for the induction of IFN. A) IFNb mRNA expression at day 4 post-
infection in LH86 cells after transfecting with a control siRNA, or siRNA against TLR3 or TLR7. Expression was calculated by the DDCt method where
uninfected cells were the experimental control and the housekeeping gene GAPDH was the internal control. Error bars represent the SEM of three
separate experiments. No virus indicates cells were cultured with the same volume in uninfected Huh7. 5 supernatant, HCV is the supernatant from
infected Huh7.5 cells as described in the methods section (MOI=0.1). B) IFNb mRNA expression at day 4 post-infection in Huh7.5 cells expressing
TLR3 or TLR7. Expression was calculated by the DDCt method as described in part A and bars represent the SEM of three separate experiments. C)
Viral replication in Huh7.5 cells expressing TLR3 or TLR7 at day 7 after infection. HCV copy numbers were calculated by real time RT-PCR run with an
HCV standard curve. D) IFNb mRNA expression at day 4 post-infection in LH86 cells with silenced RIG-I. Methodology as described in part A. E) IFNb
mRNA expression at day 4 post-infection in Huh7.5 cells transfected with RIG-I. Methodology as described in part A. F) Viral replication in Huh7.5 cells
transfected with RIG-I after 7 days of culture. Methodology as described in part C.
doi:10.1371/journal.pone.0021186.g002
to UV light for 15 minutes. B) IFNb mRNA expression of different dilutions of virus (1:1 MOI=0.1) from day 0 and day 4 post infection calculated by the
DDCt method (determined as in part A). C) IFNb mRNA expression of LH86 cells electroporated with in vitro transcribed HCV/JFH-1 or its non-
replicating counterpart HCV/JFH-GND (day 0 is the day of the electroporation). Expression was calculated as described for part A.
doi:10.1371/journal.pone.0021186.g001
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(Birmingham, AL). Nuclei were counterstained with DAPI (Vector
Laboratories Inc, Burlingame, CA), followed by examination
under a fluorescence microscope (Olympus).
Western blot analysis
Cells were washed with PBS and lysed in RIPA buffer (150 mM
sodium chloride, 1% Nonidet P-40, 0.5% sodium deoxycholate,
0.1% SDS, and 50 mM Tris-Cl [pH 8.0] supplemented with
2 mg/mL of aprotinin, 2 mg/mL of leupeptin, 40 mg/mL of
phenylmethylsulfonyl fluoride, and 2 mM DTT). Twenty mgo f
protein was electrophoresed on a 10% SDS-polyacrylamide gel
and transferred to a polyvinylidene difluoride membrane (Bio-
Rad, Hercules CA). The membranes were then blocked overnight
at 4uC in blocking buffer (PBS containing 0.1% Tween 20 (PBS-T)
and 5% fat-free milk power) followed by probing with each specific
primary antibody (see immunofluorescence section for primary
antibodies and mouse anti-human b-actin from Santa Cruz
Biotechnology) for one hour at room temperature. After washing
thrice with PBS-T for 10 minutes each, the membrane was
incubated with the appropriate HRP-conjugated secondary
antibody (all from Santa Cruz Biotechnology), diluted in PBS-T,
for 1 hour at room temperature and washed 3 more times.
Proteins were visualized with Supersignal West Pico Chemilumi-
nescent Substrate (Pierce Biotechnology, Inc, Rockford, IL).
Flow Cytometry
Pelleted cells were incubated for 30 min at room temperature
with antibodies (as in immunofluorescence section), washed with
staining buffer (PBS +2% BSA +0.1% Na azide), and then fixed
with 2% paraformaldehyde and stored at 4uC. For intracellular
staining the BDcytofix/cytoperm kit (BD biosciences) was used
with the antibodies following the manufacturer’s protocol. Cells
were analyzed on a FACSCalibur flow cytometer (BD Biosciences,
Heidelberg, Germany). Quantitation was done by the CellQuest
software (BD Biosciences; version 3.2.1). Isotype-specific immu-
noglobulin controls were run for each fluorochrome. Thirty
thousand cells were analyzed for each sample.
The Annexin V-FITC apoptosis was assayed as described
previously (BD Pharmingen, San Diego, CA) [23]. A minimum of
30,000 events per sample were acquired on a FACSCalibur Flow
Cytometer (BD Pharmingen, San Diego, CA) and subsequently
analyzed with CellQuest software (BD Biosciences; version 3.2.1,
San Diego, CA).
Results
HCV induction of IFN in LH86 cells depends on active
viral replication
We recently reported the induction of IFNb by the hepatoma
cell line LH86 in response to HCV [16]. Hence our first
experiment was to corroborate that the IFN induced by LH86
cells leads to a functional response to the virus. We measured the
expression of two interferon-stimulated-genes (ISGs) by Real time
RT-PCR: 1-8U and G1P3 in these cells with or without viral
infection by Real time RT-PCR. The experiment showed a fully
functional IFN response with the production of both these ISGs.
We then analyzed the expression of TLR3, TLR7 and RIG-I in
LH86. Immunofluorescence and flow cytometry demonstrated a
strong expression of RIG-I and TLR3 as well as a mild expression
of TLR7 in these cells which was similar to primary hepatocytes,
which were stained for comparison (data not shown). Therefore we
used this system to examine if IFNb expression correlates with
functional HCV. We infected LH86 cells with HCV strain JFH-1
(genotype 2a) at a MOI of 0.1 or with the same amount of virus
which was either heated at 72uC or exposed directly to UV light
for 15 minutes. As seen in Figure 1A, induction of IFNb expression
correlated with intact virus, since inactivating the virus by heating
or UV treatment down-regulated IFNb expression.
In order to further understand the kinetics of this interaction we
cultured LH86 cells with different dilutions of the virus. The data
showed that IFN induction was titer-dependent (Figure 1B). To
corroborate that viral replication, and not only RNA itself, is
responsible for the induction of IFN, we electroporated LH86 cells
with in vitro transcribed JFH-1 RNA or JFH-1/GND RNA. The
JFH-1/GND virus has a mutation in its RdRp which prevents its
replication but it is otherwise the same as JFH-1 [18]. We found
that JFH-1, and not JFH-1/GND, induced IFNb in LH86 cells
indicating that there is a dependence on replication for its
induction (Figure 1C). Interestingly, the basal levels of IFN after
transfecting JFH-1/GND was comparable to LH86 cells by
themselves (Compare Figure 1C with 1A) and we observed no
down-regulation as we did with full virus (genetic material plus
virion).
Both TLRs and RIG-I play a role in the induction of IFN by
HCV
The role of TLRs and RIG-I in directly recognizing HCV or
modulating its replication has not been fully characterized. We
decided to do that by using a comparative cell culture system
based on the distinct innate immune phenotype of two hepatoma
cell lines: LH86 and Huh7.5. The first, LH86 cells, are a well-
differentiated hepatoma cell line that has a fully functional set of
PRRs and is capable of inducing IFN in response to HCV
infection [16]. Conversely, Huh7.5 cells do not express TLR3 or
TLR7, and have a RIG-I mutation, which may be a reason why
these cells are so permissive to viral replication [3,24,25]. To test
this hypothesis, we first silenced TLR3 and TLR7 in LH86 cells
using specific siRNAs. As shown in Figure 2A, silencing these
receptors abrogated the IFN response in LH86 cells. Conversely,
transfecting TLR3 or TLR7 into Huh7.5 cells, followed by viral
infection, rendered the cells capable of IFN induction (Figure 2B).
Furthermore, forced expression of the same receptors into Huh7.5
cells significantly inhibited viral replication levels in these normally
permissive cells (Figure 2C). Interestingly, the expression of RIG-I
did not show the same phenomenon. While removal of RIG-I
from LH86 cells significantly abrogated the IFNb mRNA
expression, delivering it into Huh7.5 cells did not increase IFN
Figure 3. RIG-I is linked to the expression of TRAIL receptors DR4 and DR5. A) TRAIL mRNA expression 4 days after infection of Huh7.5 cells
expressing RIG-I, TLR3 or TLR7. Expression was calculated by the DDCt method where uninfected cells were the experimental control and the
housekeeping gene GAPDH was the internal control. Error bars represent the SEM of three separate experiments. B) DR4 mRNA expression 4 days
after infection of Huh7.5 cells expressing RIG-I, TLR3 or TLR7 following the methodology described in A. C) DR5 mRNA expression 4 days after
infection of Huh7.5 cells expressing RIG-I, TLR3 or TLR7 following the methodology described in part A. D) TRAIL mRNA expression 4 days after
infection of LH86 cells silenced for RIG-I, TLR3 or TLR7 calculated as described for part A. E) DR4 mRNA expression 4 days after infection of LH86 cells
with silenced RIG-I, TLR3 or TLR7 calculated as described for part A. F) DR5 mRNA expression 4 days after infection of LH86 cells with silenced RIG-I,
TLR3 or TLR7 calculated as described for part A. G) Phase view (100X magnification) of transfected cells 7 days after infection. Top row are LH86 cells
and bottom row Huh7.5 cells. The labels note what each cell was transfected with.
doi:10.1371/journal.pone.0021186.g003
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levels of Huh7.5 cells transfected with TLRs (150 versus 2 fold and
14 versus 2 fold respectively, Figures 2D and 2E) although it also
considerably reduced the level of viral replication (Figure 2F).
Cell death through RIG-I in response to HCV is linked to
the TRAIL pathway
Our previously published results showed that cytopathic effects
in LH86 are related to the induction of TRAIL and its receptors
DR4 and DR5, therefore we decided to investigate the
relationship between the PRRs and the expression of these three
genes [16]. As seen in figure 3, an interesting pattern appeared:
forced expression of the PRRs in Huh7.5 cells increased the
expression of the three genes studied (TRAIL, DR4, and DR5 in
figures 3A, 3B and 3C respectively), but only silencing RIG-I, and
not TLRs, had a profound effect on the expression of DR4 and
DR5 after HCV infection (Figure 3D, 3E and 3F). Furthermore,
RIG-I transfected Huh7.5 cells had visibly increased cell death
comparable to the susceptibility of LH86 cells to HCV infection
(Figure 3G).
TLR3 and TLR7 suppress HCV RNA replication in
hepatoma cells
To determine the functional role of TLR3 and TLR7, we
examined the relationship between viral replication and the IFN
response in a long-term culture system. The cells were infected
with HCV-JFH1 virus and samples were collected every 2–3 days
up to 75 days. Viral RNA replication levels were determined by
real-time RT-PCR analysis. As shown in Figure 4, both TLR3 and
TLR7 had a profound effect on viral replication throughout the
time of analysis. The cells with both TLR3 and TLR7 suppressed
HCV replication, while TLR3 has the most profound effect
(Figure 4A). To test whether this antiviral effect correlates with an
IFN response, we quantified IFNb expression by real time RT-
PCR. As shown in Figure 4B, over-expressing TLR3 in Huh7.5
cells induced a strong IFN production only in the first week, while
TLR7 induced a very low level of IFN. TLR3 has at least two
potential signaling pathways: NF-kB or IRF-3 cascades. To
determine which pathway is operative under these conditions, we
measured the expression of cytokines specific for each pathway
(RANTES which is IRF-3 induced and IP-10 which is NF-kB
induced) [26,27,28]. We observed that IP-10 was down-regulated
in Huh7.5 TLR3 cells throughout the culture while RANTES was
induced and sustained throughout the culture period indicating
that the down regulation of viral replication correlates with the
induction of the IRF-3 pathway without apparent NF-kB
activation (Figure 4C).
HCV can down-regulate the expression of TLR3 and RIG-I
in LH86 cells
Since TLR3 and RIG-I have different functions, we hypothe-
sized that their combined activation could lead to viral clearance.
To test this hypothesis, we co-transfected the Huh7.5 TLR3 and
TLR7 stable cell lines with RIG-I. We also did co-transfections of
TLR3 and TLR7 cells with PKR, a different cytosolic receptor.
While TLR7 did synergize with RIG-I to induce a strong IFN
response, the TLR3/RIG-I combination did not show this effect.
In these cells, contrary to our hypothesis, HCV infection down
regulated IFN (Figure 5A). Furthermore, these effects are specific
to TLR/RIG-I co-expressions in HCV infection since co-
transfecting with PKR did not synergize or disrupt the IFN
normally induced by either cell.
It has been reported that NS3/4A modulates TLR and RIG-I
pathways at the level of the adaptor proteins TRIF and IPS-1
[24,29]. Interestingly, studies have also demonstrated that
expression of TLR3 and RIG-I are also reduced in HCV patients,
therefore we decided to examine if there is a correlation between
the expression of these receptors and virus infection. We measured
the levels of both PRRs after infection with different dilutions of
the virus. As shown in Figure 5B, HCV was able to reduce the
level of TLR3 and RIG-I in a titer dependent manner.
Furthermore, the virus proteins needed to be intact for TLR3
down regulation, since heating the virus prevented this down-
regulation; similarly, RIG-I down regulation required intact virus
but it also needed replicating virus since UV-inactivation
abrogated the down-regulation of RIG-I, but not TLR3
(Figure 5C).
HCV envelope proteins down regulate the expression of
TLR3 and RIG-I
The observations just described combined with our initial
evidence (Figure 1A) demonstrates that non-replicating virus can
down-regulate IFN which indicates there is likely a role by virion
proteins in immune-evasion. To understand how these HCV
proteins can impact the innate immune system we created stable
cell lines with LH86 expressing three viral proteins: core, envelope
(E1/E2) and NS3/4A (already known to affect IFN expression)
[30]. These stable cell lines were infected with HCV at an MOI of
0.1 as before and the IFN response was measured. As expected,
LH86 cells transfected with NS3/4A had a reduced IFN peak at
day 4 as compared to control cells (Figure 6A). In contrast, LH86
cells transfected with core or envelope did not induce IFN. Core-
transfected cells did have an earlier peak (not shown) but by day 4
IFN was no different than uninfected cells. Conversely, LH86 cells
that harbored the envelope proteins did not express IFN at any
time point during a 7 day culture and at day 4 the basal IFN
expression on those cells was down regulated as well. Furthermore,
these transfected cells were able to down-regulate the levels of
TLR3 (Figure 6B) and RIG-I (Figure 6C) but only the envelope-
transfected cells maintained the down-regulation of RIG-I after
HCV infection.
Our data indicates that virion proteins are involved in evasion
through the down-regulation of the expression of TLR3 and RIG-
I. We also show that envelope proteins have bigger role in this
evasion than other viral proteins tested. To corroborate the role of
envelope in affecting the function of these receptors examined the
kinetics of IFN induction in LH86 cells, with or without
transfected envelope proteins, after Poly I:C stimulation. It is
known that this ligand stimulates both RIG-I (by transfection of
poly I:C) and TLR3 (when added directly to the media). Both
transfected poly I:C (Figure 6D) and extracellular poly I:C
(Figure 6E) were able to induce IFN in the absence of E1E2
Figure 4. A strong initial IFN response is induced an IRF-3 response by TLR3 but is not enough to clear HCV. A) Viral replication in
Huh7.5 cells stably transfected with TOPO (control) TLR3 or TLR7 infected with HCV MOI of 0.1 and collected every 2–3 days for RNA isolation (total 75
days). The HCV copy numbers from each time points were calculated by real time RT-PCR and compared against an HCV standard curve. B) IFNb
mRNA expression of the experiment described in part A. Expression was calculated by the DDCt method where uninfected cells were the
experimental control and the housekeeping gene GAPDH was the internal control. Error bars represent the SEM of three separate experiments. C) IP-
10 and RANTES mRNA expression of the experiment described in part A. Methodology as described for part B.
doi:10.1371/journal.pone.0021186.g004
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LH86 cells stimulated with extracellular poly I:C for one day,
while it completely abrogated the IFN response to transfected poly
I:C. These results show that E1E2 can interfere with the RIG-I
pathway, but only modestly interfere with TLR3-mediated IFN
induction pathway.
Discussion
The establishment of new in vitro models for the study of HCV
has introduced some of the current concepts of how it interacts
with the immune response and provided insight into these
mechanisms. In the present study we observed that initial HCV’s
replication correlates strongly with the production of IFNb in
hepatocytes and that these responses are linked to the recognition
of HCV by TLR3, and RIG-I. All these molecules have been
strongly implicated as targets of viral evasion [24,29,31]. Previous
studies have demonstrated that both TLR3 and RIG-I pathways
are direct targets of NS3/4A serine protease of HCV. Further-
more, both receptors are: active in normal liver cells, known to
induce type I IFN, share many of the same pathways and are
capable of up-regulating each other [3,32,33,34,35,36]. Studies
have shown that either TLR3 or RIG-I is required or that both
produce the same effect [33,37]. Our data shows that different
stimuli can induce distinct effects. While studying their mecha-
nisms we demonstrated that TLR3 and RIG-I have specific roles
during HCV infection: TLR3 was strongly involved in the
induction of IFNs and creating an IRF-3 dependent environment
that helps keep the viral replication low. RIG-I, on the other hand,
can also involve the induction of cellular apoptosis through the
TRAIL pathway and the death receptors DR4 and DR5. In
addition, we also uncovered a potential mechanism of evasion by
the viral envelope protein. Our data shows an inverse correlation
on the presence of viral envelope proteins in hepatocytes with a
decrease in the mRNA expression of both TLR3 and RIG-I.
Furthermore, the stable expression of the envelope protein
prevented the stimulation of RIG-I by poly (I:C) in the cytosol.
We showed a direct correlation between viral titers and levels of
IFNb suggesting that a threshold needs to be reached before an
appropriate response is developed. This corroborates previously
published data that also shows a delayed IFN response in HCV
infection [34]. They also showed that TLR3’s role in HCV was to
induce IFN, IRF-3 activation and ISG induction in HCV-infected
liver cells both in vitro and in clinical samples which correlates with
our findings [3,34]. Furthermore, our data suggests that the
amount of IFN induced by HCV depends on the expression levels
of TLR3 itself at the time of infection.
Based on our study, it is likely that the combination of both
receptors should be optimal for the clearance of HCV infection. Our
data demonstrates that RIG-I’s main role may lie in the induction of
apoptosis a function which was recently demonstrated for helicases
[37,38,39,40,41]. We linked the induction of TRAIL-induced
apoptosis in HCV to RIG-I and in particular to DR4 and DR5.
This effect is usually attributed in other infections to TLR3 but
although both TLR and RIG-I were able to up-regulate TRAIL,
DR4 and DR5, when present, only the latter had a profound effect in
the expression level of both death receptors. In general our findings
can have strong implications in the study of the consequences of
chronic infection since cytopathic effects have been implicated in the
pathogenesis of HCV-induced liver injury in a TRAIL-dependent
manner [42,43,44,45]. Furthermore, clinically the levels of TRAIL
are up regulated in chronic patients which correlate the availability of
TRAIL with the induction of liver damage [46,47].
Figure 5. The expression of TLR3 and RIG-I is affected by intact
virion proteins in hepatocytes A) IFNb mRNA expression in Huh7.5
TLR3 or TLR7 stable cell lines co-transfected with either PKR or RIG-I after
infection with HCV MOI=0.1. Expression was calculated by the DDCt
method where uninfected cells were the experimental control and the
housekeeping gene GAPDH was the internal control. Error bars represent
theSEMofthreeseparateexperiments.B)TLR3andRIG-ImRNAexpression
levels 7 days after infection with different HCV dilutions (methodology as
in figure 1C). C) TLR3 and RIG-I gene expression levels 7 days after infection
with normal, heated or UV-treated virus calculated as described in part A.
doi:10.1371/journal.pone.0021186.g005
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disrupted the induction of IFNb seen with either receptor alone.
This observation argues that the virus might exert certain
pressure when they are in combination since this combination of
receptors has been demonstrated to induce IFN in the absence
of HCV [33,48]. In these studies, the authors observed no
synergistic effect between the receptors which led them to argue
that there was no direct interaction with each other. Our overall
data supports the idea that these two receptors may interact
with each other and that they have specific functions in HCV
infection (Figure 7). This discrepancy made us investigate the
role of HCV on the levels of these receptors. We observed that
the expression levels of TLR3 and RIG-I were down regulated
after infection in LH86 cells. Our finding correlates with clinical
observation, which shows that the levels of these receptors in
patients are down regulated [5]. In our system those effects were
mediated by intact viral proteins, in particular the virion
proteins: core and envelope. These results correlate well with
our recent studies on healthy myeloid-derived dendritic cells
where virus did not replicate but was able to induce
phenotypical changes as well as modulate the cytokine secretion
[49]. Similarly, a recent report on HCV in vitro studies
demonstrated that viral infection can specifically down regulate
another receptor, TLR7 and envelope proteins have been
directly linked to the blocking of the TRAIL pathway which
could be mechanistically explained by the down regulation of
RIG-I [16,50,51,52]. This further supports our theory of the
initial interaction of the virus with its host being dependent on
Figure 6. Envelope proteins affect the response to non-HCV responses through RIG-I receptor but only temporarily through TLR3.
A) IFNb gene expression of stably transfected LH86 cells expressing Core, E1E2 or NS3/4A 4 days after HCV infection. Expression was calculated by the
DDCt method where uninfected cells were the experimental control and the housekeeping gene GAPDH was the internal control. Error bars
represent the SEM of three separate experiments. B) TLR3 mRNA expression 7 days after infection of stably transfected LH86 cells carrying the HCV
proteins Core, E1/E2 or NS3/4A. Expression determined as described in part A. E) RIG-I mRNA expression 7 days after infection of stably transfected
LH86 cells carrying HCV proteins Core, E1/E2 or NS3/4A. Expression determined as described in part A. D) IFNb mRNA expression of LH86 cells or LH86
stably transfected with E1/E2 treated with 50 mg/mL transfected Poly I:C. Expression was calculated as described in part A. E) IFNb mRNA expression of
LH86 cells or LH86 stably transfected with E1/E2 treated with 50 mg/mL extracellular Poly I:C. Expression determined as described in part A.
doi:10.1371/journal.pone.0021186.g006
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immune responses (Figure 7). Further studies would reveal if this
correlation is indeed an evasion strategy of HCV and what
might be the mechanism for this phenomenon.
In summary, we have characterized the interaction of HCV
with innate immune molecules, TLR3, TLR7, and RIG-I. We
found that TLR3 and TLR7 play an important role in controlling
viral infection through the IFN production, while RIG-I play a
role in IFN induction as well as in the induction of hepatocyte
apoptosis. We also found that the presence of viral E1E2 protein
correlates with lower TLR3 and RIG-I expression, a possible
mechanism of HCV evasion of innate immune response. Beyond
IFN, future studies should aim at understanding the specific role of
NF-kB and IRF-3 cascades, on why the virus seems to choose one
pathway over the other, and how this might interfere with viral
clearance.
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Figure 7. Schematics of the initial interaction of HCV in hepatocytes. Virus binds and gets in the cells were nucleic acid or replication
induces the host cells innate immunity through the induction of apoptosis (mediated by RIG-I) and IFNb (through TLR3 engagement). While
the replication of the virus leads to the development of viral proteins like NS34A that interact downstream of these effects (red arrow line)
there is a possible earlier evasion strategy performed by virion proteins that lead to the down regulation of RIG-I and TLR3 preventing
apoptosis and the induction of IFNb. Apoptosis is particularly prevented by down regulating TRAIL receptors, DR4 and DR5, and IFNb by
preventing NF-kB pathways such as the one that induces IP-10. Together all of these factors help the cell survive and the virus to persist in the
host’s hepatocytes.
doi:10.1371/journal.pone.0021186.g007
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